| |
Significant patient populations, top clinical institutions, and ease of regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠ 
|
|
Today's Big NewsOct 19, 2022 |
|
Sino Biological offers rapid mouse monoclonal antibody development service on the Beacon®️ platform and obtains positive clones within 35 days, which accelerates the process of antibody (drug) discovery. Learn more. 
|
|
| By Nick Paul Taylor Jazz Pharmaceuticals has thrown its hat into the HER2 ring. For $50 million, the company has secured the chance to pay a further $325 million to take Zymeworks’ HER2-directed bispecific antibody forward after the release of pivotal data. |
|
|
|
By Max Bayer With $20 million on hand and the second part of a potentially registrational phase 2/3 study just getting underway, Ayala was facing a potential cash crunch. But Advaxis may have solved its problems—in return for the hope of a return to the Nasdaq. |
Sponsored By Cullinan Oncology Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive. |
Sponsored By PathAI TME research is recognized as one of the most promising areas in oncology drug development. AI-powered digital pathology reveals new insights previously hidden by laborious manual pathology methods. |
By James Waldron The FDA has pumped the brakes on PTC Therapeutics’ Huntington's disease trial in the U.S. even as the studies kick into gear in other countries. |
By James Waldron Ambrx has been mulling major changes since August. Now it has confirmed what form these will take: narrowing its cancer pipeline to earlier-stage therapies and dumping its lead asset at the expense of 15% of its workforce. |
By Nick Paul Taylor Almost two years after phase 3 results on the leading COVID-19 vaccines started rolling in, Providence Therapeutics has posted midphase data on its mRNA candidate and outlined plans to move into a pivotal booster study. |
By Gabrielle Masson Uganda is implementing another measure to combat the current Ebola outbreak, with plans to dole out investigational vaccines in about two weeks. |
By Angus Liu Gilead Sciences has new data showing COVID drug Veklury maintained efficacy despite changes in a coronavirus structure it targets, just as the company explores expedited ways to launch a pivotal trial for an investigational oral antiviral. |
By Andrea Park President Joe Biden may have declared the COVID-19 pandemic “over” in the U.S., but that news doesn’t appear to have reached the makers of diagnostic tests for the virus. |
By Kevin Dunleavy Merck KGaA’s problems in France over its thyroid drug Levothyrox aren’t going away. Seven months after France’s highest court confirmed an earlier civil court ruling that ordered the Germany-based company to compensate users who suffered problems from Levothyrox, the case has advanced at the judicial level. On Tuesday, a judge in Marseille opened a formal probe to determine if the company provided misleading information when switching the formulation of Levothyrox. |
By Paige Minemyer The company released its quarterly earnings report on Wednesday morning. Profits were up 7.2% from the prior-year quarter, where Elevance Health posted $1.5 billion. |
By Fraiser Kansteiner Alongside the christening of a new manufacturing plant in Dublin Wednesday, Spanish plasma specialist Grifols has received a thumbs-up on its Rigel-partnered platelet disorder drug from a nearby cost watchdog in the U.K. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about the explosion of consumer-initiated lab testing. Also under discussion is our special report on the key issues and trends with Medicare Advantage. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now. 
|
|
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
